Study of GC101 TIL in Brain Glioma (Soochow2)

NCT ID: NCT04943913

Last Updated: 2025-12-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-06
• Study Completion Date: 2027-05-31

Brief Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant glioma . Autologous TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Conditions

Glioma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tumor Infiltrating Lymphocytes

1x10\^9-5x10\^10 in vitro expanded autologous TILs will be infused i.v. to patients with brain glioma after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Group Type: EXPERIMENTAL

Tumor Infiltrating Lymphocytes (TIL)

Intervention Type: BIOLOGICAL

Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.

Interventions

Tumor Infiltrating Lymphocytes (TIL)

Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Age: 18 years to 75 years;

2. Histologically diagnosed as primary/relapsed/metastasized brain glioma;

3. Expected life-span more than 3 months;

4. Karnofsky≥60% or ECOG score 0-2;

5. Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.

6. Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated;

7. At least 1 evaluable tumor lesion;

8. Hematology and Chemistry（within 7 days prior to enrollment）:

• Absolute count of white blood cells≥2.5×10^9/L;
• Absolute count of neutropils≥1.5×10^9/L;
• Absolute count of lymphocytes ≥0.7×109/L；
• Platelet count≥100×10^9；
• hemoglobin≥90 g/L;
• Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);
• International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);
• Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min;
• Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN);
• Totol bilirubin≤1.5×ULN;

9. No absolute or relative contraindications to operation or biopsy;

10. Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion；

11. Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs;

12. Be able to understand and sign the informed consent document;

13. Be able to stick to follow-up visit plan and other requirements in the agreement.

Exclusion Criteria

1. Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;

2. Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%;

3. Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc.

4. Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;

5. Severe physical or mental diseases;

6. Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection);

7. Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy;

8. History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy;

9. Having received immunotherapy and developed irAE level greater than Level 3;

10. Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded);

11. Females in pregnancy or lactation;

12. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy;

13. Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Second Affiliated Hospital of Soochow University

OTHER

Sponsor Role: collaborator

Shanghai Juncell Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Qing Lan

Role: PRINCIPAL_INVESTIGATOR

Second Affiliated Hospital of Soochow University

Locations

The Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Site Status: RECRUITING

Countries

China

Central Contacts

GC Clinical

Role: CONTACT

clinicaltrials@juncell.com

086-18001759113

Facility Contacts

Lan Qing

Role: primary

szlq006@163.com

+86 0512 67784089

Other Identifiers

GC101-2021-Soochow2-BGM

Identifier Type: -

Identifier Source: org_study_id